About VectivBio
VectivBio is a Healthcare company based in Basel (Switzerland) founded in 2019, and was acquired by Ironwood Pharma in May 2023. Transformative therapeutics for rare diseases are developed. VectivBio has raised $145 million across 3 funding rounds from investors including Ironwood Pharma, TD Securities and Citadel. VectivBio has completed 1 acquisition, including Comet Therapeutics. VectivBio offers products and services including LINZESS and Pipeline Products. Its focus areas include Life Sciences, Gastroenterology, Drugs and Bowel Disorders.
Company details
Developer of transformative therapeutics for rare diseases The lead product is Apraglutide which is a synthetic GLP-2 analog for the treatment of short bowel syndrome. It is designed to increase the intestines ability to absorb fluid and nutrients to minimize parenteral support and improve patient health.
- Headquarters Basel, Switzerland
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website vectivbio.com
- Social LinkedIn X
- Acquired by Ironwood Pharma (May 2023)
- Total Equity Funding$145M (USD)
in 3 rounds
- Latest Funding Round$54M (USD), Post-IPO
Jul 2022
- InvestorsIronwood Pharma
& 11 more
- Investments & Acquisitions
- Acquired byIronwood Pharma
(May 2023)
Products & Services of VectivBio
VectivBio offers a comprehensive portfolio of products and services, including LINZESS and Pipeline Products.
Treats irritable bowel syndrome and chronic constipation.
Advances new therapies for gastrointestinal conditions.
Funding Insights of VectivBio
VectivBio has successfully raised a total of $145M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $54 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $145M
- Total Rounds 3
- Last Round Post-IPO — $54M
- First Round $35M
(Jan 2020)
- Investors Count 11
All 3 funding rounds of VectivBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2022 | $54M | Post-IPO | – | – | |
| Oct 2020 | $110M | Series D | – | Citadel, Cormorant Capital | |
| Jan 2020 | $35M | Series C | – | Versant Ventures, Orbimed | – |
12 investors in total: 12 institutional.
Investors in VectivBio
VectivBio has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Ironwood Pharma, TD Securities and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on lifescience and healthcare sectors | forbion.com | Naarden, Netherlands | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Investments are directed toward early-stage healthcare companies in France. | 2000 | inserm-transfert.fr | Paris, France | |
Long, short, event-driven, and multiple strategies are employed by Citadel. | 1990 | citadel.com | Chicago, United States | |
Sourcing and deploying capital for real estate investments and developments. | cormorant-capital.com | New York, United States | ||
Eventide Mutual Funds is managed by Eventide Asset Management, offering investment solutions. | eventidefunds.com | Boston, United States | ||
Corporate consultancy, advisory, and funding services are provided to businesses. | 2012 | bpifrance.com | Maisons Alfort, France | |
Investment advisory services are provided to financial clients. | 1986 | teklacap.com | Boston, United States |
Investor details for VectivBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of VectivBio
30 people are tracked at VectivBio (17 in leadership, 6 in board & advisors, 7 in team).
| Name | Role | Group |
|---|---|---|
Alain Bernard | Chief Technology Officer | Leadership |
Martine Mazzetti | Chief of Staff | Leadership |
Claudia D’Augusta | Chief Financial Officer | Leadership |
Christian Meyer | Chief Development Officer | Leadership |
Scott Applebaum | Chief Legal Officer & Corporate Secretary | Leadership |
Omar Khwaja | Chief Medical Officer | Leadership |
Kevin Harris | Chief Commercial Officer | Leadership |
Marie-Agnes Bagnard | Director, Clinical Process Lead | Leadership |
Volker Nickel | Vice President, Head Of Corporate Quality And Compliance | Leadership |
Jemima Warrack | Director, Patient Advocacy (global) | Leadership |
Marco André F. | Head Of Information Technology | Leadership |
Pablo Pinna Prieto | Vice President, Finance | Leadership |
Federico Bolognani | Vice President, Head Of Clinical Development | Leadership |
Dan Donahue | Senior Director, Head Of U.s. Clinical Operations | Leadership |
Luca J. Fehr | Director Corporate Controller | Leadership |
Isabelle Statovci | Senior Director - Clinical Science | Leadership |
Ayshea Kring | Director Clinical Operations | Leadership |
Thomas F. Woiwode | Chair | Board & advisors |
Hans Schikan | Board Member | Board & advisors |
Paul R. Carter | Board Member | Board & advisors |
10 more people are available in the full profile.
Complete people profiles for VectivBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by VectivBio
VectivBio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Comet Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Enzyme substitution therapy for neurological diseases is developed. | comettherapeutics.com | Cambridge, United States | 2017 | Aug 2021 | •••• |
Complete acquisition details for VectivBio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of VectivBio
6 dated milestones of VectivBio across 4 years, from founding to its latest funding, stage changes and deals.
- Founded VectivBio is founded.
- Funding First funding round of $35.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Comet Therapeutics.
- Funding Latest funding round, Post-IPO, of $54.0M.
- Exit Acquired by Ironwood Pharma.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vectivbio
Complete news archive for VectivBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VectivBio
VectivBio was founded in 2019 and raised its 1st funding round 1 year after it was founded.
VectivBio is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
VectivBio is a funded company, having raised a total of $145M across 3 funding rounds to date. The company's 1st funding round was a Series C of $35M, raised on Jan 2020.
Developer of transformative therapeutics for rare diseases The lead product is Apraglutide which is a synthetic GLP-2 analog for the treatment of short bowel syndrome. It is designed to increase the intestines ability to absorb fluid and nutrients to minimize parenteral support and improve patient health.
VectivBio offers LINZESS and Pipeline Products.
VectivBio has made 1 acquisition, including Comet Therapeutics.
VectivBio has 12 investors. Key investors include Ironwood Pharma, TD Securities, Citadel, Orbimed, and Bpifrance.
Yes. VectivBio was acquired by Ironwood Pharma in May 2023.